{"id":"shr3824","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL4297431","moleculeType":"Small molecule","molecularWeight":"454.88"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"SHR3824 works by binding to the molecular target, which results in the desired therapeutic effect.","oneSentence":"SHR3824 is a small molecule targeting the molecular target.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:34:30.819Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Unknown"}]},"trialDetails":[{"nctId":"NCT07441187","phase":"","title":"Efficacy and Safety of Henagliflozin, Retagliptin, and Metformin Extended-Release Tablets in Chinese Patients With Type 2 Diabetes Mellitus","status":"NOT_YET_RECRUITING","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2026-02-20","conditions":"T2DM (Type 2 Diabetes Mellitus)","enrollment":300},{"nctId":"NCT07323381","phase":"PHASE4","title":"Effects of Henagliflozin Proline and Metformin XR on Body Composition in Geriatric Patients With Newly Diagnosed T2DM","status":"NOT_YET_RECRUITING","sponsor":"Bin Lu","startDate":"2025-12-30","conditions":"Diabetes Type 2","enrollment":116},{"nctId":"NCT07294495","phase":"NA","title":"Effect of Henagliflozin on Myocardial Fibrosis in Non-Obstructive HCM: A Randomized, Double-Blind, Placebo-Controlled Trial Using 68Ga/18F-FAPI PET/CMR","status":"NOT_YET_RECRUITING","sponsor":"Shanghai East Hospital","startDate":"2026-01-07","conditions":"HCM - Hypertrophic Cardiomyopathy","enrollment":150},{"nctId":"NCT06187727","phase":"PHASE4","title":"Henagliflozin Reducing Infarct Size After Priamry PCI in Patients With ST Segment Elevation Myocardial Infarction","status":"COMPLETED","sponsor":"Qian geng","startDate":"2023-07-01","conditions":"Myocardial Infarction, Heart Failure","enrollment":248},{"nctId":"NCT06221059","phase":"PHASE2","title":"Efficacy and Safety of HRS-1780 Tablets and Henagliflozin Proline Tablets in Patients With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2024-03-02","conditions":"Chronic Kidney Disease","enrollment":181},{"nctId":"NCT06888050","phase":"PHASE4","title":"Efficacy and Safety of Henagliflozin Proline and Metformin Hydrochloride Extended-release Tablets (Ⅰ) Versus Metformin Tablets in Patients With New-onset Type 2 Diabetes: a Multicenter, Randomized Controlled Study","status":"RECRUITING","sponsor":"Zhejiang Provincial People's Hospital","startDate":"2025-04-11","conditions":"New-onset Type 2 Diabetes","enrollment":268},{"nctId":"NCT06818851","phase":"PHASE4","title":"The Effects of Henagliflozin on Glucose Fluctuation and Immunosenescence in Type 2 Diabetes Patients on Insulin Therapy","status":"RECRUITING","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2025-07-14","conditions":"Diabetes Mellitus, Type 2","enrollment":64},{"nctId":"NCT06085703","phase":"NA","title":"Effects of Henagliflozin on the Brain Function in T2DM Patients With Mild Cognitive Impairment: a Randomized, Parallel Controlled Clinical Trial","status":"COMPLETED","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2024-04-01","conditions":"Type 2 Diabetes Mellitus, Mild Cognitive Impairment","enrollment":24},{"nctId":"NCT06959030","phase":"","title":"An Observational Study on the Safety and Efficacy of Henagliflozin in Chinese Patients With Type 2 Diabetes","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangxi Medical University","startDate":"2025-06-19","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":10000},{"nctId":"NCT07027774","phase":"PHASE4","title":"Effect of Henagliflozin on Renal Outcomes in Non-dialysis Patients With Advanced Chronic Kidney Disease : A Multicenter Prospective, Randomized Controlled Trial（HERO -aCKD）","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wannan Medical College","startDate":"2025-07-10","conditions":"Chronic Kidney Disease Stage 4","enrollment":429},{"nctId":"NCT05677334","phase":"PHASE4","title":"Combination of Henagliflozin and Continuous Subcutaneous Insulin Infusion in T2DM","status":"COMPLETED","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2023-03-01","conditions":"Type2diabetes","enrollment":210},{"nctId":"NCT06762223","phase":"PHASE4","title":"Henagliflozin on Liver Fibrosis in Patients with MASLD and T2DM","status":"NOT_YET_RECRUITING","sponsor":"Xiqiao Zhou","startDate":"2024-12-31","conditions":"Metabolic Dysfunction-associated Steatotic Liver Disease, Type 2 Diabetes Mellitus","enrollment":190},{"nctId":"NCT06495931","phase":"PHASE1","title":"Study on Drug Interaction of HRS-1780 Tablets, Henagliflozin Tablets, Metformin Tablets and HRS-7535 Tablets in Healthy Human","status":"NOT_YET_RECRUITING","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2024-07","conditions":"Type 2 Diabetes Mellitus","enrollment":24},{"nctId":"NCT06448130","phase":"PHASE4","title":"Henagliflozin's Impact on Prediabetes Remission","status":"NOT_YET_RECRUITING","sponsor":"Shandong Provincial Hospital","startDate":"2024-06","conditions":"PreDiabetes, Prediabetic State, Type 2 Diabetes","enrollment":984},{"nctId":"NCT06417489","phase":"PHASE4","title":"Evaluation of Efficacy and Safety of Combination Therapy of Henagliflozin Proline, Retagliptin and Metformin in New Diagnosed Type 2 Diabetes Patients","status":"NOT_YET_RECRUITING","sponsor":"Peking University First Hospital","startDate":"2024-05-31","conditions":"Type 2 Diabetes","enrollment":160},{"nctId":"NCT06218342","phase":"PHASE4","title":"Henagliflozin in Relieving Type 2 Diabetes With Non-alcoholic Fatty Liver Disease","status":"UNKNOWN","sponsor":"Sir Run Run Shaw Hospital","startDate":"2024-02-15","conditions":"Type 2 Diabetes, Non-Alcoholic Fatty Liver Disease","enrollment":156},{"nctId":"NCT06216340","phase":"PHASE4","title":"Efficacy of Henagliflozin for Weight Loss in Obesity Without Diabetes","status":"NOT_YET_RECRUITING","sponsor":"The First People's Hospital of Changzhou","startDate":"2024-02-15","conditions":"Obese, Weight Loss, Pre-diabetes","enrollment":300},{"nctId":"NCT06083116","phase":"PHASE1","title":"Drug-Drug Interaction Study Between Henagliflozin Proline and Hydrochlorothiazide","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-08-28","conditions":"Diabetes in Adults","enrollment":12},{"nctId":"NCT06059287","phase":"NA","title":"The Effect of Henagliflozin and Metformin on Myocardial Tissue-level Characteristics","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2023-10-01","conditions":"Obesity, Type 2 Diabetes, Sodium-glucose Co-transporter-2 Inhibitor","enrollment":64},{"nctId":"NCT06031389","phase":"NA","title":"Henagliflozin Delays the Progress of Diabetic Nephropathy Via Regulates Gut-Renal Axis","status":"UNKNOWN","sponsor":"Qianfoshan Hospital","startDate":"2024-01-01","conditions":"Diabetic Nephropathies","enrollment":120},{"nctId":"NCT05682495","phase":"PHASE1","title":"A HR20031 BE Study on Healthy Subjects","status":"COMPLETED","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2023-01-31","conditions":"Type 2 Diabetes","enrollment":96},{"nctId":"NCT05742230","phase":"NA","title":"Effect of Henagliflozin on Cardiac Function in Type 2 Diabetes Patients With Chronic Heart Failure (HERO-HF)","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-04-15","conditions":"Heart Failure","enrollment":1932},{"nctId":"NCT05252624","phase":"PHASE3","title":"Henagliflozin in Patients With Atrial Fibrillation","status":"UNKNOWN","sponsor":"Beijing Anzhen Hospital","startDate":"2022-09-01","conditions":"Atrial Fibrillation","enrollment":100},{"nctId":"NCT05108350","phase":"PHASE1","title":"A Study to Assess the Bioequivalence of Fixed Dose Combination of HR20033 Relative to Co-administration of the Individual Components in Healthy Chinese Subjects","status":"UNKNOWN","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2021-11-09","conditions":"Type II Diabetes","enrollment":80},{"nctId":"NCT04390295","phase":"PHASE3","title":"Efficacy and Safety of SHR3824 in Combination With Metformin in Subjects With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2017-11-02","conditions":"Type 2 Diabetes Mellitus","enrollment":450},{"nctId":"NCT03329118","phase":"PHASE1","title":"Drug-drug Interaction Between Simvastatin and SHR3824","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2017-11-24","conditions":"Type 2 Diabetes","enrollment":12},{"nctId":"NCT03160014","phase":"PHASE1","title":"Safety and Pharmacokinetics/Pharmacodynamics of SHR3824 in Patients With Hepatic Impairment","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2015-06","conditions":"Hepatic Impairment","enrollment":32},{"nctId":"NCT03159832","phase":"PHASE1","title":"Safety and Pharmacokinetics/Pharmacodynamics of SHR3824 in Type 2 Diabetes Patients With Renal Insufficient","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2015-06","conditions":"Renal Insufficiency,Type 2 Diabetes","enrollment":24},{"nctId":"NCT03159052","phase":"PHASE3","title":"Efficacy and Safety of SHR3824 as Monotherapy in Subjects With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2017-06","conditions":"Type 2 Diabetes Mellitus","enrollment":450},{"nctId":"NCT02500485","phase":"PHASE1","title":"The Drug-drug Interaction of SHR3824 and SP2086","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2015-05","conditions":"Type 2 Diabetes","enrollment":12},{"nctId":"NCT02354027","phase":"PHASE1","title":"The Drug-drug Interaction of SHR3824 and Metformin","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2014-09","conditions":"Type 2 Diabetes","enrollment":12},{"nctId":"NCT02366377","phase":"PHASE1","title":"The PK/PD, Efficacy, Safety and Tolerability Study of SHR3824 in Combination With Metformin in Type 2 Diabetes Mellitus Patients","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2015-02","conditions":"Type 2 Diabetes Mellitus","enrollment":168},{"nctId":"NCT02366351","phase":"PHASE1","title":"The PK/PD, Efficacy, Safety and Tolerability Study of SHR3824 in Type 2 Diabetes Mellitus Patients","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2015-02","conditions":"Type 2 Diabetes Mellitus","enrollment":168},{"nctId":"NCT02361138","phase":"PHASE1","title":"The PK/PD Study of Multiple Dose of SHR3824 in Healthy Volunteers","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2013-12","conditions":"Type 2 Diabetes","enrollment":48},{"nctId":"NCT02356224","phase":"PHASE1","title":"The PK/PD Study of Single Dose of SHR3824 in Healthy Volunteers","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2013-06","conditions":"Type 2 Diabetes","enrollment":84},{"nctId":"NCT02353975","phase":"PHASE1","title":"Effect of a High-fat Meal on the Pharmacokinetics of SHR3824 and Mass Balance Study in Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2014-05","conditions":"Type 2 Diabetes","enrollment":12},{"nctId":"NCT02346175","phase":"PHASE1","title":"Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of SHR3824 in Type 2 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2014-06","conditions":"Type 2 Diabetes Mellitus","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Henagliflozin"],"phase":"phase_3","status":"active","brandName":"SHR3824","genericName":"SHR3824","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SHR3824 is a small molecule targeting the molecular target. Used for Unknown.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}